Exploring characteristics of haemodialysis patients related to successful individual application of bioimpedance to help determine the endpoint of dialysis treatment

Exploring characteristics of haemodialysis patients related to successful individual application of bioimpedance to help determine the endpoint of dialysis treatment - Biolyse

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46424

Enrollment

120

Registered

2018-10-30

Start date

2018-07-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease kidney disease

Interventions

Bioimpedance

Dry weight

Haemodialysis

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: ESRD patients undergoing intermittent daytime haemodialysis treatment at Ziekenhuis Gelderse Vallei in Ede Undergoing routine HD treatment for at least three months

Exclusion criteria

Exclusion criteria: Pacemaker Metal implants Major amputations Pregnancy Restless legs Dementia

Design outcomes

Primary

Measure	Time frame
The primary endpoint constitutes whether BIA can be successfully used to determine the endpoint of HD treatment. Success is hereby defined as post-HD normovolemia as assessed by BIA.	—

Secondary

Measure	Time frame
Secondary parameters include nutritional status, body composition, and the presence of comorbidities.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)